OVID

1.67

4.02% -0.07

Handel nachbörslich: 1.70 0.03 +1.80%

Ovid Therapeutics Inc (OVID)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.74

Offen:

$1.82

24-Stunden-Volumen:

3.95M

Relative Volume:

1.30

Marktkapitalisierung:

$118.75M

Einnahmen:

$391.70K

Nettoeinkommen (Verlust:

$-52.34M

KGV:

-2.2267

EPS:

-0.75

Netto-Cashflow:

$-45.92M

1W Leistung:

-9.24%

1M Leistung:

+33.60%

6M Leistung:

+554.90%

1J Leistung:

+53.21%

1-Tages-Spanne:

$1.65

$1.84

1-Wochen-Bereich:

$1.57

$1.89

52-Wochen-Spanne:

$0.2425

$2.01

Ovid Therapeutics Inc Stock (OVID) Company Profile

Firmenname

Ovid Therapeutics Inc

Sektor

Healthcare (1141)

Branche

Biotechnology (637)

Telefon

212-776-4381

Adresse

441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY

Mitarbeiter

Twitter

@OvidRx

Nächster Verdiensttermin

2024-11-04

Neueste SEC-Einreichungen

OVID's Discussions on Twitter

Vergleichen Sie OVID mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OVID Ovid Therapeutics Inc	1.67	123.73M	391.70K	-52.34M	-45.92M	-0.75
VRTX Vertex Pharmaceuticals Inc	407.79	106.37B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	460.46	59.90B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	564.63	60.40B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	796.92	49.56B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.10	36.88B	4.56B	-176.77M	225.30M	-1.7177

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-08	Fortgesetzt	B. Riley Securities	Buy
2024-06-18	Herabstufung	Oppenheimer	Outperform → Perform
2024-04-30	Eingeleitet	B. Riley Securities	Buy
2024-04-29	Eingeleitet	H.C. Wainwright	Buy
2024-04-05	Eingeleitet	Wedbush	Outperform
2023-12-21	Eingeleitet	BTIG Research	Buy
2023-10-13	Eingeleitet	Oppenheimer	Outperform
2021-04-20	Herabstufung	Cantor Fitzgerald	Buy → Neutral
2021-03-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2020-12-02	Herabstufung	Citigroup	Buy → Neutral
2020-12-02	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2019-09-04	Eingeleitet	RBC Capital Mkts	Outperform
2018-04-20	Eingeleitet	Ladenburg Thalmann	Buy

Alle ansehen

Ovid Therapeutics Inc Aktie (OVID) Neueste Nachrichten

Oct 10, 2025

OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - TradingView

Oct 10, 2025

Will Ovid Therapeutics Inc. benefit from macro trendsWeekly Profit Summary & Long Hold Capital Preservation Tips - newser.com

Oct 10, 2025

Real time pattern detection on Ovid Therapeutics Inc. stock2025 Bull vs Bear & Short-Term Trading Alerts - newser.com

Oct 10, 2025

Ovid Therapeutics Inc Stock Analysis and ForecastStock Rotation Strategies & Exceptional Trading Strategies - earlytimes.in

Oct 10, 2025

Market reaction to Ovid Therapeutics Inc.’s recent newsRate Hike & Breakout Confirmation Alerts - newser.com

Oct 10, 2025

Oct 09, 2025

Ovid Therapeutics (OVID) Surges on Positive Analyst Rating - GuruFocus

Oct 09, 2025

Ovid spikes as Wedbush moves to Outperform on lead asset - Seeking Alpha

Oct 09, 2025

Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says - MarketScreener

Oct 09, 2025

Technical signs of recovery in Ovid Therapeutics Inc.IPO Watch & Risk Controlled Swing Alerts - newser.com

Oct 09, 2025

What data driven models say about Ovid Therapeutics Inc.’s futureWeekly Risk Report & High Yield Equity Trading Tips - newser.com

Oct 09, 2025

What drives PSP Swiss Property AG Common Stock P7S0 stock priceCapital Gains Strategies & Follow Top Performers in the Community - earlytimes.in

Oct 09, 2025

Is Ovid Therapeutics Inc. (1OT) stock vulnerable to rate hikesJuly 2025 Retail & Capital Efficiency Focused Ideas - newser.com

Oct 09, 2025

Detecting price anomalies in Ovid Therapeutics Inc. with AITrade Volume Report & Real-Time Buy Zone Alerts - newser.com

Oct 09, 2025

Tools to assess Ovid Therapeutics Inc.’s risk profileEarnings Growth Summary & Weekly Chart Analysis and Guides - newser.com

Oct 09, 2025

Oct 07, 2025

Hudson Yards seizure drug company raises $81M after cutting expenses - Crain's New York Business

Oct 07, 2025

What analysts say about Ovid Therapeutics Inc 1OT stockStock Rotation Strategies & Minimal Capital Investment - earlytimes.in

Oct 07, 2025

Ovid Therapeutics (OVID): Evaluating Valuation After Positive Phase 1 Trial Results and $175 Million Financing - Sahm

Oct 07, 2025

Oct 06, 2025

Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know - Yahoo Finance

Oct 06, 2025

Wedbush Adjusts Price Target on Ovid Therapeutics to $5 From $3, Maintains Outperform Rating - MarketScreener

Oct 06, 2025

What’s next for Ovid Therapeutics Inc. stock priceJuly 2025 Rallies & Stock Timing and Entry Methods - newser.com

Oct 06, 2025

Ovid Therapeutics Sets Market Trends with Successful Trials - Kalkine Media

Oct 06, 2025

Oct 05, 2025

Ovid Therapeutics Inc. announced that it has received $80.8108 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Blue Owl Healthcare Opportunities, ADAR1 Capital Management, LLC, Affinity Asset Advisors, LLC - MarketScreener

Oct 05, 2025

Forecasting Ovid Therapeutics Inc. price range with options data2025 Technical Overview & Daily Stock Trend Watchlist - newser.com

Oct 05, 2025

Why Ovid Therapeutics Inc. stock is popular among millennialsJuly 2025 Big Picture & Weekly Market Pulse Updates - newser.com

Oct 05, 2025

Oct 04, 2025

Ovid Therapeutics rises on $175 million placing and research update - The Pharma Letter

Oct 04, 2025

Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results - Yahoo Finance

Oct 04, 2025

Ovid announces positive topline results for the - GlobeNewswire

Oct 04, 2025

Oct 03, 2025